Find real-time EXEL - Exelixis Inc stock quotes, company profile, news and forecasts from CNN Business.  Industry Rank, Ranked of 484 Within this trend it has completed 3rd of 5th up and 4th wave correction is in progress. Oppenheimer increased their target price on shares of Exelixis from $33.00 to $37.00 and gave the stock an outperform rating in … Learn more. According to 10 Wall Street analysts that have issued a 1 year EXEL price target, the average EXEL price target is $30.60, with the highest EXEL stock price forecast at $40.00 and the lowest EXEL stock price forecast at $25.00. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Receive a free world-class investing education from MarketBeat. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. A number of other brokerages have also issued reports on EXEL. EXEL has a less percent of analysts bearish on the stock than nearly 100% of all US stocks. Exelixis, Inc. (EXEL) estimates and forecasts The dark blue line represents the company's actual price. Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 7.05%, respectively, for the quarter ended September 2020. Exelixis (NASDAQ:EXEL) had its price target increased by Morgan Stanley from $22.00 to $23.00 in a research report sent to investors on Friday morning, BenzingaRatingsTable reports. In a report issued on December 11, H.C. Wainwright also maintained a Buy rating on the stock with a $14.00 price target. On average, analysts give Exelixis, Inc. a Strong Buy rating. What price target have analysts set for EXEL? View Price Target for EXEL Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Friday, July 13, 2018. A number of other research analysts also recently issued reports on the stock. The firm presently has an “equal weight” rating on the biotechnology company’s stock. The current analyst and expert consensus on Exelixis is Buy, with 0 strong sell and 7 strong buy opinions. View which stocks are hot on social media with MarketBeat's trending stocks report. Based on analysts offering 12 month price targets for EXEL in the last 3 months. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Exelixis Inc's average analyst price target is … Exelixis Inc (#EXEL - US) is in uptrend and out-performing to SPX in last uptrend. It follows that stock’s current price would jump +94.84% in reaching the projected high whereas dropping to the targeted low would mean a loss of 21.77% for stock’s current value. The average twelve-month price objective among brokerages that have covered the stock in the last year is $30.27. The average analyst price target of EXEL is greater than 58.44% of Healthcare stocks. Learn about financial terms, types of investments, trading strategies and more. … Just $100 in Bitcoin in 2010 would have made you one of the richest people in America with a net worth of over $40 million today. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Intraday data delayed at least 15 minutes or per exchange requirements. Get daily stock ideas top-performing Wall Street analysts. The most common way Exelixis analysts use to provide recommendation to the public is financial statements analysis. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Their average twelve-month price target is $31.78, suggesting a possible upside of 33.9%. Tuesday, January 16, 2018. Asia Today: Australia OKs Pfizer vaccine, to begin in Feb. eBay (NASDAQ: EBAY) Earnings Report: Here’s What to Watch For, 3 Clean Energy Stocks that Could Get Boosted by Biden, Why These 3 ETFs Should be in Your 2021 Portfolio, Buy Kinder Morgan, Inc While It Still Yields 6.75%. Exelixis, Ipsen report positive cancer-study results MarketWatch. All rights reserved. The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Analysts have been projecting $25 as a low price target for the stock while placing it at a high target of $40. The number of analysts covering the stock of EXEL is higher than 86.25% of Healthcare stocks. EXEL price target in 14 days: 25.996 USD* upside and 21.155 USD* downside. Just enter your email address below. EXEL has a lower change in bullishness amongst analysts than nearly 100% of all US stocks. More So far 739,778 shares have traded compared to … See what's happening in the market right now with MarketBeat's real-time news feed. EXEL has been the topic of several analyst reports. In recent trading, shares of Exelixis Inc (Symbol: EXEL) have crossed above the average analyst 12-month target price of $24.30, changing hands for $24.56/share. Make investment decisions regarding EXEL using the data that counts. They currently have an equal weight rating on the biotechnology company’s stock. See today’s analyst top recommended stocks >> Exelixis (EXEL) In a report released yesterday, Andy Hsieh from William Blair maintained a Buy rating on Exelixis. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. (Highest and lowest possible predicted price in a 14 day period) Detailed Trend Components of the Exelixis Inc Stock Price Forecast & Prognosis Watch closely and buy if comes at reasonable price. Fundamental company data provided by Morningstar and Zacks Investment Research. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Copyright © 2021. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. 07:40 AM ET. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. After a Post-Earnings Drop, is it Time to Ride PetMed Express? Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com! Exelixis (NASDAQ:EXEL) had its target price cut by Morgan Stanley from $29.00 to $27.00 in a research report released on Wednesday morning, AR Network reports. On September 22, 2020 "Morgan Stanley" gave "Equal Weight" rating for EXEL. There’s a big reason why this company’s shares are on the move, You don’t want to miss out on a chance to be a part of this innovative company who is becoming a powerful weapon on the fight against Covid-19. Get short term trading ideas from the MarketBeat Idea Engine. Looking for new stock ideas? Trade Grade Analyst Price Target on EXEL. The lighter blue line represents the stock's consensus price target. Analyst Commentary and Balance Sheet Since the company provided 2021 guidance, Needham ($33 price target), Oppenheimer ($35 price target) and RBC Capital all … Do Not Sell My Information. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Stifel Nicolaus lifted their target price on Exelixis from $26.00 to $27.00 and gave the company a “hold” rating in a … The high price target for EXEL is $40.00 and the low price target for EXEL is $27.00. The average price target represents a 28.56% increase from the last price of $23.73. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy.".  Peer Grade in Biotech. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. View our full suite of financial calendars and market data tables, all for free. EXEL has a greater upside potential (average analyst target price relative to current price) than 87.34% of stocks in the mid market cap category. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Their average twelve-month price target is $31.78, predicting that the stock has a possible upside of 42.50%. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The high price target for EXEL is $40.00 and the low price target for EXEL is $27.00. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. What is EXEL's Price Target? Their forecasts range from $27.00 to $40.00. Business Wire - 2 months ago To see all exchange delays and terms of use please see disclaimer. 1y Target Est 30.83 Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. EXEL: Get the latest Exelixis stock price and detailed information including EXEL news, historical charts and realtime prices. Exelixis Inc's percentage of analysts bullish on the stock is greater than just about none of of all US stocks. The chart below shows how a company's share price and consensus price target have changed over time. Do the numbers hold clues to what lies ahead for the stock? A number of other research analysts have also recently issued reports on EXEL. The average price target is $30.8, which means analysts expect … They currently have an equal weight rating on the biotechnology company’s stock. 10 equities research analysts have issued 12 month price objectives for Exelixis' stock. Their average twelve-month price target is $31.78, predicting that the stock has a possible upside of 41.93%. You can opt out at any time. Trending Tickers The company’s shares closed last Friday at $19.95.  Buy & Hold Grade Volume today is low. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXEL stock is a recommendation set at 2.00. Enjoy free access to the POWR Ratings for all stocks and ETFs on the quote pages. Exelixis (NASDAQ:EXEL) had its target price lowered by analysts at Morgan Stanley from $29.00 to $27.00 in a report issued on Wednesday, Benzinga reports. The average price target is $30.50 with a high forecast of $35.00 and a low forecast of $27.00. Start Your Risk-Free Trial Subscription Here, Tufin Software (NYSE: TUFN) Stock is Ready for Multiple Expansion. EXEL has a less variance in analysts' estimates than 27.37% of Business Services stocks. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Piper Sandler raised their price target on shares of Exelixis from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, September 21st.

Cheese Wizards Cafe, Battleship Game Theory, Moldy Peaches Movie, Seinfeld Season 1 Episode 1 Dailymotion, Are You Sleeping Lyrics In Spanish, Baby Girl Maxi Dress, Molecular Pathology Fellowship, Is Swoobat Good,